Please login to the form below

Not currently logged in
Email:
Password:

MyoKardia

This page shows the latest MyoKardia news and features for those working in and with pharma, biotech and healthcare.

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Other partnerships in Sanofi's Sunrise initiative include a $200m cardiomyopathy project with MyoKardia, and funding agreements with start-ups Warp Drive Bio - focusing on the use of genomics to discover

Latest news

  • Sanofi licenses cardiomyopathy programme in $200m deal Sanofi licenses cardiomyopathy programme in $200m deal

    Sanofi licenses cardiomyopathy programme in $200m deal. Has rights to three of MyoKardia’ s programmes. ... MyoKardia's approach targets the genetic mutations that are the underlying causes of cardiomyopathy, addressing the fundamental mechanisms of

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2014 Pharma deals during September 2014

    It certainly would have been simpler, but probably more expensive, if Sanofi had acquired MyoKardia! ... That may still be on the cards as Sanofi has made an equity investment in MyoKardia as part of the upfront.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    209. MyoKardia/ Sanofi. Licence and collaboration. 5. Three programmes for treatment of genetic forms of cardiomyopathy.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    MyoKardia appoints COO and medical affairs VP. Dr June Lee and Dr Radhika Tripuraneni join the precision medicines specialist. ... California, US-based MyoKardia has appointed Dr June Lee as chief operating officer and Dr Radhika Tripuraneni as vice

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    Jonathan Fox leaves AstraZeneca for MyoKardia. Will lead programme to target genetic heart disease. ... Commenting on his appointment, he highlighted MyoKardia's potential in treating genetic heart disease. “

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics